Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib

  • Montemurro M
  • Schöffski P
  • Reichardt P
 et al. 
  • 32


    Mendeley users who have this article in their library.
  • 106


    Citations of this article.


Patients diagnosed with advanced gastrointestinal stromal tumours (GISTs) who are resistant or intolerant to both imatinib and second-line sunitinib have a poor prognosis and few therapeutic options. We evaluated the efficacy of nilotinib, a novel tyrosine kinase inhibitor (TKI) in patients pretreated with imatinib and sunitinib. Fifty-two consecutive patients treated with oral nilotinib, 400 mg twice daily, within the nilotinib compassionate use programme in 12 European cancer centres, were included in this retrospective analysis. Median age was 59 years (range 24-80), and all patients had WHO performance score better than 3. All patients had failed both imatinib and sunitinib pretreatment, either due to progressing GIST (96%) or intolerance (4%). Five patients (10%; 95% confidence interval (CI) 2-18) responded to nilotinib and 19 patients (37%; 95% CI 24-50) achieved a disease stabilisation. Nilotinib was generally well tolerated, but six patients (12%) discontinued treatment due to intolerance. Median progression-free survival of nilotinib treatment was 12 weeks (95% CI 9-15; range 0-104) and median overall survival was 34 weeks (95% CI 3-65; range 2-135). Nilotinib is active in GIST resistant to both imatinib and sunitinib. These results warrant further investigation of nilotinib in GIST. © 2009 Elsevier Ltd. All rights reserved.

Author-supplied keywords

  • Compassionate use
  • GIST
  • Gastrointestinal stromal tumour
  • Imatinib
  • Nilotinib
  • Sunitinib
  • Tyrosine kinase inhibitor

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text


  • M. Montemurro

  • P. Schöffski

  • P. Reichardt

  • H. Gelderblom

  • J. Schütte

  • J. T. Hartmann

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free